Cemiplimab Combo Does Not Show Superior ORR to Anti-PD-1 Monotherapy in Advanced HNSCCDecember 13th 2018
The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma, according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.
No Survival Benefit Found With Durvalumab in Head and Neck CancerDecember 10th 2018
AstraZeneca has reported that the phase III EAGLE trial has missed its primary endpoint, as patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy did not see a survival benefit with durvalumab alone or combined with tremelimumab.
Despite Advances, Interpreting Data From Genomics and Precision Medicine LagsOctober 25th 2018
I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Financial Advocacy Grows Under the Value-Based SystemOctober 24th 2018
Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
ACCC President Reignites Resilience in Oncology CaregiversOctober 23rd 2018
Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid TumorsOctober 22nd 2018
Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?October 19th 2018
Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Promising Activity Seen With Palbociclib/Cetuximab Combo in HPV-Unrelated HNSCCJuly 12th 2018
An overall response rate of 39% was induced with the combination of the CDK4/6 inhibitor palbociclib and cetuximab in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma.